Volume : 13, Issue : 06, June – 2026
Title:
A COMPREHENSIVE REVIEW: ASSESSMENT OF THERAPEUTIC EFFECTIVENESS AND HEALTH RELATED QUALITY OF LIFE OUTCOMES OF ADJUVANT TERIPARATIDE THERAPY IN ORTHOPEDIC CARE
Authors :
Anjana.A, Aleena Anson, Jasna Mariyam T.N, Shifana.K.S,Mrs. Rajasree. S, Dr .T. Tamilselvan
Abstract :
A serious public health concern, osteoporosis and accompanying fragility fractures significantly lower functional independence and health-related quality of life (HRQoL) in older populations. Conventional antiresorptive medications frequently fail to avoid mechanical hardware failures in complex orthopedic cases or speed up acute bone healing in tertiary care hospital settings. The therapeutic efficacy, radiological results, treatment sequencing strategies, and quality-of-life advantages of adjuvant teriparatide [recombinant human parathyroid hormone, $rhPTH(1-34)$] therapy for orthopedic patients are assessed in this review. With an emphasis on spinal, hip, and sacral insufficiency fractures, a thorough synthesis of multi-centric clinical trials, prospective randomized controlled trials, and real-world retrospective assessments was carried out. Standardized, established quality-of-life measurements, namely the Short Form-12 (SF-12) and the Quality of Life Questionnaire of the European Foundation for Osteoporosis (QUALEFFO-41), were used to critically evaluate patient-reported functional results and well-being. The combined evidence shows that teriparatide significantly increases systemic bone mineral density (BMD), encourages high-quality trabecular consolidation, and improves early radiographic bone repair. Perioperative teriparatide improves periprosthetic bone remodeling, guarantees pedicle screw stability, and dramatically lowers structural fixation failures such as implant subsidence and proximal junctional kyphosis (PJK). Additionally, switching from teriparatide to later antiresorptive regimens (such denosumab or alendronate) provides the best clinical route for long-term skeletal preservation.
Significant improvements in physical component states and acute mechanical pain management are revealed by standardized assessment scores from the SF-12 and QUALEFFO-41 tests, enabling quicker post-operative mobilization and a quicker return to independent living. In the end, incorporating teriparatide into tertiary orthopedic care protocols effectively bridges the gap between systemic biological bone recovery and mechanical hardware fixation, offering a highly effective, patient-centered pathway that successfully transitions people from immobility following a fracture to a state of restored health-related quality of life.
Keywords: Teriparatide, Fragility Fracture, Orthopedic Surgery, Health-Related Quality of Life (HRQoL), SF-12, QUALEFFO-41.
Cite This Article:
Please cite this article in press Anjana.A et al., A Comprehensive Review: Assessment Of Therapeutic Effectiveness And Health Related Quality Of Life Outcomes Of Adjuvant Teriparatide Therapy In Orthopedic Care, Indo Am. J. P. Sci, 2026; 13(06).
REFERENCES:
1. Chiba K, Okazaki N, Kurogi A, et al. Randomized controlled trial of daily teriparatide, weekly high-dose teriparatide, or bisphosphonate in patients with postmenopausal osteoporosis: The TERABIT study. Bone. 2022 Jul;160:116416.
2. Yukishima T, Ebina K, Etani Y, et al. Impact of switching from bisphosphonates to denosumab, teriparatide, or romosozumab in patients with postmenopausal osteoporosis: a case-control study. Osteoporos Int. 2025 Mar;36(3):531-538.
3. Chandran M, Akesson KE, Javaid MK, et al. Impact of osteoporosis and osteoporosis medications on fracture healing: a narrative review. Osteoporos Int. 2024 Aug;35(8):1337-1358.
4. Shibuya Y, Katsumi K, Ohashi M, et al. Effect of adjuvant therapy with teriparatide in patients with thoracolumbar osteoporotic vertebral fractures who underwent vertebroplasty with posterior spinal fusion. Sci Rep. 2022 May 25;12(1):8854.
5. Veronese N, Briot K, Guañabens N, et al. Recommendations for the optimal use of bone forming agents in osteoporosis. Aging Clin Exp Res. 2024 Aug 9;36(1):167.
6. Kobayakawa T, Kanayama Y, Hirano Y, et al. Therapy with transitions from one bone-forming agent to another: a retrospective cohort study on teriparatide and romosozumab. JBMR Plus. 2024 Oct 23;8(12):ziae131.
7. Lee SY, Seo MS, Yoo JI. Effectiveness of Weekly Teriparatide Injection in Postmenopausal Patients with Hip Fractures. Clin Orthop Surg. 2023 Aug;15(4):552-559.
8. Yoo JI, Ha YC, Ryu HJ, et al. Teriparatide Treatment in Elderly Patients With Sacral Insufficiency Fracture. J Clin Endocrinol Metab. 2017 Feb 1;102(2):560-565.
9. Tabatabai L, Cosman F, Curtis JR, et al. Comparative Effectiveness of Abaloparatide and Teriparatide in Women 50 Years of Age and Older: Update of a Real-World Retrospective Analysis. Endocr Pract. 2025 Feb;31(2):159-168.
10. Mori S, Hagino H, Sugimoto T, et al. Sequential therapy with once-weekly teriparatide injection followed by alendronate versus monotherapy with alendronate alone in patients at high risk of osteoporotic fracture: final results of the Japanese Osteoporosis Intervention Trial-05. Osteoporos Int. 2023 Jan;34(1):189-199.
11. Park JH, Kwon O, Choi JH, et al. Perioperative teriparatide for preventing proximal junctional kyphosis and failure in patients with osteoporosis after adult thoracolumbar spinal deformity surgery: a prospective randomized controlled trial. Osteoporos Int. 2025 May;36(5):833-843.
12. Sheng OC, Wu WT, Peng CH, Yao TK, Chen IH, Wang JH, Yeh KT. Therapeutic advantage of teriparatide in very elderly patients with proximal femoral fractures: a functional and BMD analysis. BMC Musculoskelet Disord. 2024 Apr 13;25(1):288.
13. Rana A, Aggarwal S, Bachhal V, Hooda A, Jindal K, Dhillon MS. Role of supplemental teriparatide therapy in management of osteoporotic intertrochanteric femur fractures. Int J Burns Trauma. 2021 Jun 15;11(3):234-244.
14. Bukata SV, Puzas JE. Orthopedic uses of teriparatide. Curr Osteoporos Rep. 2010 Mar;8(1):28-33.
15. Fu SC, Lu YC, Sie NH, et al. Pre-teriparatide anti-osteoporosis medication therapy and fracture-related hospitalization in patients at very high fracture risk. Osteoporos Int. 2026 Jun 2. [Epub ahead of print].
16. Kim SY, Zhang M, Bockman R. Bone Mineral Density Response from Teriparatide in Patients with Osteoporosis. HSS J. 2017 Jul;13(2):171-177.
17. Välimäki VV, Mäkitie O, Pereira R, Laine C, Wesseling-Perry K, Määttä J, Kirjavainen M, Viljakainen H, Välimäki MJ. Teriparatide Treatment in Patients With WNT1 or PLS3 Mutation-Related Early-Onset Osteoporosis: A Pilot Study. J Clin Endocrinol Metab. 2017 Feb 1;102(2):535-544.
18. Tanavalee C, Ngarmukos S, Amarase C, Tantavisut S, Jaruthien N, Tanavalee A. A randomized controlled trial of teriparatide for accelerating bone union and improving clinical outcomes in patients with pertrochanteric fracture fixation. Sci Rep. 2025 Jun 3;15(1):19465.
19. Niimi R, Kono T, Nishihara A, Hasegawa M, Kono T, Sudo A. Efficacy of Daily Teriparatide Treatment in Low Levels of Walking State Patients. Clin Drug Investig. 2017 Jun;37(6):551-557.
20. Niimi R, Kono T, Nishihara A, Hasegawa M, Matsumine A, Kono T, Sudo A. Usefulness of daily teriparatide treatment in elderly patients over 80 years of age. Osteoporos Int. 2016 May;27(5):1869-74.
21. Huang TW, Huang KC, Lin SJ, Chuang PY, Shih HN, Lee MS, Hsu RW, Shen WJ. Effects of teriparatide on cementless bipolar hemiarthroplasty in patients with osteoporotic femoral neck fractures. BMC Musculoskelet Disord. 2016 Jul 19;17:300.
22. Luo L. Application of teriparatide in CKD-related osteoporosis: efficacy and safety considerations. Int Urol Nephrol. 2025 Oct;57(10):3475-3476.
23. Park CH, Yoo JI, Choi CH, Suh YS. The impact of sequential therapy from short-term teriparatide to denosumab compared with denosumab alone in patients with osteoporotic hip fracture: a 1-year follow-up study. BMC Musculoskelet Disord. 2020 Nov 14;21(1):751.
24. Gariffo G, Bottai V, Falcinelli F, Di Sacco F, Cifali R, Troiano E, Capanna R, Mondanelli N, Giannotti S. Use of Teriparatide in preventing delayed bone healing and nonunion: a multicentric study on a series of 20 patients. BMC Musculoskelet Disord. 2023 Mar 11;24(1):184.
25. Mishra S, Satapathy D, Samal S, Zion N, Lodh U. Role of Supplemental Teriparatide Therapy to Augment Functional and Radiological Outcomes in Osteoporotic Intertrochanteric Hip Fractures in the Elderly Population. Cureus. 2022 Jun 22;14(6):e26190.
26. Kim YH, Ha KY, Bae HW, Park HY, Ko YI, Ko MS, Kim SI. The Effects of Longer Use of Teriparatide on Clinical and Radiographic Outcomes after Spinal Fusion in Geriatric Patients. Medicina (Kaunas). 2024 Jun 6;60(6):946.
27. Watts NB, Aggers D, McCarthy EF, Savage T, Martinez S, Patterson R, Carrithers E, Miller PD. Responses to Treatment With Teriparatide in Patients With Atypical Femur Fractures Previously Treated With Bisphosphonates. J Bone Miner Res. 2017 May;32(5):1027-1033.
28. Shinohara A, Ueno Y, Marumo K. Weekly teriparatide therapy rapidly accelerates bone healing in pyogenic spondylitis with severe osteoporosis. Asian Spine J. 2014 Aug;8(4):498-501.
29. Han S, Wen SM, Zhao QP, Huang H, Wang H, Cong YX, Shang K, Ke C, Zhuang Y, Zhang BF. The Efficacy of Teriparatide in Improving Fracture Healing in Hip Fractures: A Systematic Review and Meta-Analysis. Biomed Res Int. 2020 Aug 20;2020:5914502.
30. Kaliya-Perumal AK, Lu ML, Luo CA, Tsai TT, Lai PL, Chen LH, Chen WJ, Niu CC. Retrospective radiological outcome analysis following teriparatide use in elderly patients undergoing multilevel instrumented lumbar fusion surgery. Medicine (Baltimore). 2017 Feb;96(5):e5996.